Motor-voice Assessment in Infants (MAMI)
NCT06807203
Autism Spectrum Disorder, Brain Damage, Chronic
Columbus, Ohio, United States
View Trial DetailsNCT Number: NCT03770832
The objective of this study is to develop an automated, precise, quantitative assay for detecting atypical motor behavior and development in infants using data from wearable sensors and video recordings.
This study is active but is not currently recruiting participants.
0 month–24 month
All sexes
Observational
Shirley Ryan AbilityLab, Chicago, Illinois, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 3 months
Error between true clinical test scores and scores estimated from sensor and video data, assessed at the 3 month time-point.
Time frame: 6 months
Error between true clinical test scores and scores estimated from sensor and video data, assessed at 6 month time-point.
Time frame: 3 months
Sensitivity and specificity of algorithm (trained on sensor and video data from the 3 month time-point) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2])
Time frame: 6 months
Sensitivity and specificity of algorithm (trained on sensor and video data from the 6 month time-point) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2])
Time frame: 1-2 weeks, 1 month, 3 months
Sensitivity and specificity of GMA scores (taken at 1-2 weeks, 1 month, 3 months) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2]). The GMA is an observational exam where an infant's spontaneous movements are scored as atypical or normal for their age.
Time frame: 6 months, 9 months, 1 year
Sensitivity and specificity of AIMS scores (taken at 6 months, 9 months, 1 year) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2]). The AIMS is a norm-referenced observational assessment with a minimum score of 0 and a maximum score of 58. Higher scores indicate better motor performance on the assessment.
Time frame: 6 months, 9 months, 1 year
Sensitivity and specificity of HINE scores (taken at 6 months, 9 months, 1 year) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2]). The HINE is a neurological exam with a minimum score of 0 and a maximum score of 78. Higher scores indicate better performance on the assessment.
Time frame: 1-2 weeks, 1 month, 3 months
Sensitivity and specificity of TIMP scores (taken at 1-2 weeks, 1 month, 3 months) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2]).
Time frame: 1-2 weeks, 1 month, 9 months, 1 year, 2 years
Error between true clinical test scores and scores estimated from sensor and video data, assessed at each remaining time-point.
Time frame: 1-2 weeks, 1 month, 9 months, 1 year, 2 years
Sensitivity and specificity of algorithm (trained on sensor and video data from the remaining time-points) to predict neuromotor outcome at 2 years (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2])
Time frame: 1 month
Sensitivity and specificity of NNNS scores (taken at 1 month) to predict neuromotor outcome at final study visit (as measured by the Peabody Developmental Motor Scales, second edition [PDMS-2])
Shirley Ryan AbilityLab
Other
Wearable Sensors and Video Recording for Children (Birth to 24 Months) to Monitor Motor Development
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06807203
Autism Spectrum Disorder, Brain Damage, Chronic
Columbus, Ohio, United States
View Trial DetailsNCT06263777
Abnormalities, Multiple, Autism Spectrum Disorder
Banī Suwayf, Beni Suweif Governorate, Egypt
View Trial DetailsNCT05860166
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Samsun, Atakum, Turkey (Türkiye)
View Trial DetailsNCT05845684
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Samsun, Atakum, Turkey (Türkiye)
View Trial Details